{"prompt": "['be summarized in terms of mean, standard deviation, minimum, and maximum.', 'Laboratory parameters will also be presented graphically over time, if appropriate.', 'All safety variables will be analyzed for the safety population. For each variable, the number', 'of available observations will be reported. The safety population includes all patients who', 'have received at least one dose of emicizumab study medication.', 'The iDMC (see Section 9.4.1) will evaluate the study data, including the emerging safety', 'results, at periodic reviews and recommend to the Sponsor whether the protocol should be', 'amended or the study should be stopped early. All summaries and analyses will be prepared', 'by the Study Management Team (SMT) statistician and presented for review by tho-iDMC', 'review. Members of the iDMC will be external to the Sponsor and will follow a charter that', 'outlines their roles and responsibilities.', '6.5', 'EFFICACY ANALYSES', 'The definition of a bleed is described in Section 4.5.7.1.- Patients will be asked to record', 'whon they have bleeds or hemophilia modication use, including emicizumab. Patients will be', 'asked to record any hemophilia medication use (including emicizumab) and information regarding', 'any bleeding events. The patients should record this information at least every week even if', \"they do not experience a bleed. The number of bleeds will be compared with patients' bleed\", 'rate prior to study entry and will be summarized descriptively.', 'As different HRQoL measures (Haem-A-QoL and the Haemo-QoL-SF) will be used for adult', 'and adolescent patients, all calculations and analyses will be conducted separately for each', 'patient population. Scale scores for the Haem-A-Qol and Haemo-QoL-SF will be calculated', 'and summarized descriptively. The HRQoL scale scores for all patients will be evaluated', 'after 6 months of treatment, a timepoint which is consistent with other recent registrational', 'studies in hemophilia (Lentz et al. 2013; Mahlangu et al. 2014; Powell et al. 2013) and', 'analyses of this type of data (Santagostino et al. 2014; Wyrwich et al. 2015). Paired t-tests', 'will be used to compare the on-treatment scores with the baseline scale scores for each', 'HRQoL measure. Within-patient changes from baseline for the different HRQoL scale scores', 'will also be calculated for each of the on-treatment timepoints. The proportion of patients', 'who report changes in each group-that exceed clinically meaningful thresholds will be', 'reported.', 'For each of the EQ-5D-5L assessments, the number and percentage of patients in each of', 'the five categories for each question for each group will be evaluated. Changes in the EQ-', '5D-5L index utility score from baseline will also be reported compared between groups. In', 'addition, summary statistics including mean, standard deviation, median, minimum, and', \"maximum will be calculated according to the patients' health state using the EuroQoL visual\", 'analogue scale (EQ-VAS) both within and between groups. The proportion of patients who', 'report changes in each group-that exceed the clinically meaningful threshold on the EQ-5D-', '5L index and the EQ-VAS scores will be reported.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '44 / Protocol MO39129, Version 3']['6.6', 'IMMUNOGENICITY ANALYSES', 'The immunogenicity analyses will include patients with at least one pre-dose and one post-', 'dose anti-emicizumab antibody assessment. The numbers and proportions of antibody-', 'positive patients and antibody-negative patients during the treatment period will be', 'summarized. Patients are considered to be antibody-positive if they are negative at baseline', 'but develop an anti-emicizumab antibody response following emicizumab study drug', 'administration (treatment-induced antibody response), or if they are positive at baseline and', 'the titer of one or more post-baseline samples is at least 4-fold greater (i.e., 0.60 titer units)', 'than the titer of the baseline sample (treatment-enhanced antibody response)', '6.9.1', 'Planned Interim Analyses', 'The first interim analysis will be performed once approximately 100 patients have received', 'treatment with emicizumab for at least 24 weeks. A second interim analysis will be', 'performed when approximately 100 patients have received treatment with emicizumab for at', 'least 52 weeks. The data from these analyses will subsequently be presented to the iDMC in', 'order to enable them to effectively monitor the study (see Section 9.4.1).', '7.3', 'ELECTRONIC PATIENT-REPORTED OUTCOME DATA', 'PRO data will be collected electronically through the use of electronic devices provided by', 'an ePRO vendor (HRQoL and EQ-5D-5L) or using a paper questionnaire (EmiPref). Paper', 'versions of the questionnaires are also available in case of ePRO outage or if an ePRO', 'device is otherwise unavailable. The electronic device is designed for entry of data in a', 'manner that is attributable, secure, and accurate, in compliance with U.S. FDA regulations', 'for electronic records: (21 Code of Federal Regulations, Part 11). The PRO data from the', 'device will be transmitted electronically to the eCRF in real time. to a centralized database at', 'the oPRO vendor. The data from the oPRO devices will be available for viewing only through', 'a secure access to a web portal provided by the ePRO vendor.-Only identified and trained', 'users may view the data, and their actions (if any) will become part of the audit trail. The', 'Sponsor will have view-only access to PRO data. Regular data transfers will occur from the', 'centralized database at the vendor to the database provided by the Sponsor.-The Sponsor', 'will receive all data (including requested meta-data) entered by the patients on the ePRO', 'devices and all relevant study documentation.', '7.6', 'RETENTION OF RECORDS', 'Records and documents pertaining to the conduct of this study and the distribution of IMP,', 'including eCRFs, ePRO data applicable), Informed Consent Forms, laboratory test results,', 'and medication inventory records, must be retained by the Principal Investigator for at least', '15 years after completion or discontinuation of the study or for the length of time required by', 'Emicizumab - F. Hoffmann-La Roche Ltd', '45 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}